Dual Recombinase-Based Mouse Models Help Decipher Cancer Biology and Targets for Therapy

Tina Sket1,2,3, Chiara Falcomatà4, Dieter Saur1,2,3

  • 1Division of Translational Cancer Research, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany.

Cancer Research
|July 14, 2023
PubMed

Insights

Genetically engineered mouse models using dual-recombinase systems (DRS-GEMMs) advance cancer research by enabling detailed study of tumor ecosystems and therapeutic responses. These models offer new ways to understand cancer drivers and validate therapeutic targets.

Area of Science:

  • Oncology
  • Genetics
  • Bioengineering

Background:

  • Next-generation sequencing and single-cell profiling reveal complex tumor ecosystems.
  • Genetically engineered mouse models (GEMMs) are crucial for studying human cancers.
  • Understanding tumor heterogeneity and host interactions is vital for effective cancer therapy.

Purpose of the Study:

  • To discuss the utility of dual-recombinase system (DRS)-based cancer GEMMs.
  • To highlight how DRS-GEMMs can model, trace, and manipulate tumor phenotypes.
  • To explore the application of DRS-GEMMs in investigating host-tumor interactions and therapy response.

Main Methods:

  • Development of genetically engineered mouse models (GEMMs) utilizing dual-recombinase systems (DRS).
  • Application of advanced sequencing and single-cell profiling techniques.
  • Functional investigation of cancer phenotypes, host interactions, and therapeutic responses within DRS-GEMMs.

Main Results:

  • DRS-based cancer GEMMs provide unprecedented opportunities to study tumor ecosystems.
  • These models facilitate the elucidation of critical drivers behind diverse tumor phenotypes.
  • DRS-GEMMs enable validation of potential therapeutic targets.

Conclusions:

  • DRS-based cancer GEMMs represent a significant advancement in cancer research.
  • These models offer powerful tools for dissecting cancer biology and response to treatment.
  • DRS-GEMMs are instrumental in validating novel therapeutic strategies.